Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment

Vibeke Bratseth, Alf-Åge Pettersen, Trine B Opstad, Harald Arnesen, Ingebjørg Seljeflot, Vibeke Bratseth, Alf-Åge Pettersen, Trine B Opstad, Harald Arnesen, Ingebjørg Seljeflot

Abstract

Background: Cardiovascular disease with disturbances in the haemostatic system, might lead to thrombotic complications with clinical manifestations like acute myocardial infarction (AMI) and stroke. Activation of the coagulation cascade with subsequent increased thrombin generation, characterizes a prothrombotic phenotype. In the present study we investigated whether prothrombotic markers were associated with risk factors and clinical subgroups in a cohort of patients with angiographically verified coronary artery disease (CAD). The patients were randomized to long-term treatment with the antiplatelet drugs aspirin or clopidogrel, and we further investigated the effect on hypercoagulability of such treatment for 1 year, of which limited data exists.

Methods: Venous blood samples were collected in fasting condition between 08:00 and 10:30 am, at baseline when all patients were on aspirin therapy (n = 1001) and in 276 patients after 1 year follow-up on aspirin or clopidogrel. In vivo thrombin generation was assessed by prothrombin fragment 1 + 2 (F1+2) and D-dimer, and the endogenous thrombin potentiale (ETP) in the calibrated automated thrombogram (CAT) assay, representing ex vivo thrombin generation. In addition soluble tissue factor (sTF) and free- and total tissue factor pathway inhibitor (TFPI) were measured.

Results: We found age to be significantly associated with F1+2 and D-dimer (β = 0.229 and β =0.417 respectively, p <0.001, both). Otherwise, only weak associations were found. F1+2 and D-dimer were higher in women compared to men (p <0.001 and p = 0.033, respectively). Smokers had elevated levels of ETP compared to non-smokers (p = 0.014). Additionally, patients on renin-angiotensin system (RAS) inhibition showed significantly higher levels of F1+2, compared to non-users (p = 0.013). Both aspirin and clopidogrel reduced levels of ETP after 12 months intervention (p = 0.003 and p <0.001, respectively) and the levels of F1+2 were significantly more reduced on aspirin compared to clopidogrel (p = 0.023).

Conclusions: In the present population of stable CAD, we could demonstrate a more hypercoagulable profile among women, smokers and patients on RAS medication, assessed by the prothrombotic markers F1+2, D-dimer and ETP. Long-term antiplatelet treatment with aspirin alone seems to attenuate thrombin generation to a greater extent than with clopidogrel alone. The study is registered at http://www.clinicaltrials.gov: NCT00222261.

References

    1. World Health Organization. Diabetes. 2009.
    1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143. doi: 10.1161/hc0902.104353.
    1. Robbie L, Libby P. Inflammation and atherothrombosis. Ann N Y Acad Sci. 2001;947:167–179.
    1. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis. 1995;6(Suppl 1):S7–S13.
    1. Rapaport SI, Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb. 1992;12(10):1111–1121. doi: 10.1161/01.ATV.12.10.1111.
    1. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 2006;208(3):327–339. doi: 10.1002/path.1871.
    1. Hemker HC, Al DR, de Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96(5):553–561.
    1. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100(8):793–798. doi: 10.1161/01.CIR.100.8.793.
    1. Solheim S, Pettersen AA, Arnesen H, Seljeflot I. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost. 2006;96(5):660–664.
    1. Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 1992;80(8):2006–2011.
    1. Pettersen A-Å R SIAMAH. Residual platelet reactivity on single aspirin treatment as related to clinical end points in patients with stable coronary artery disease. Results from the ASCET trial. 2012. Am Heart Assoc. 2012. Ref Type: Generic. 10-1161/JAHA.112.000703.
    1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. et al.Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol. 2005;4(4):198–203. doi: 10.1097/00132577-200512000-00018.
    1. Hemker HC, Giesen P, Al DR, Regnault V, De Smedt E, Wagenvoord R. et al.Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4–15. doi: 10.1159/000071636.
    1. Opstad TB, Pettersen AA, Weiss T, Arnesen H, Seljeflot I. Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J. 2010;8:7. doi: 10.1186/1477-9560-8-7.
    1. Cadroy Y, Pierrejean D, Fontan B, Sie P, Boneu B. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. Nouv Rev Fr Hematol. 1992;34(1):43–46.
    1. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA. et al.Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol. 1997;97(4):775–784. doi: 10.1046/j.1365-2141.1997.1222936.x.
    1. Haidl H, Cimenti C, Leschnik B, Zach D, Muntean W. Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT) Thromb Haemost. 2006;95(5):772–775.
    1. van Hylckama Vlieg1, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol. 2007;138(6):769–774. doi: 10.1111/j.1365-2141.2007.06738.x.
    1. Ossei-Gerning N, Wilson IJ, Grant PJ. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. Thromb Haemost. 1998;79(4):736–740.
    1. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 1993;98(1):83–90. doi: 10.1016/0021-9150(93)90225-J.
    1. Caponnetto P, Russo C, Di MA, Morjaria JB, Barton S, Guarino F. et al.Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study. Eur J Clin Invest. 2011;41(6):616–626. doi: 10.1111/j.1365-2362.2010.02449.x.
    1. Cacciola RR, Guarino F, Polosa R. Relevance of endothelial-haemostatic dysfunction in cigarette smoking. Curr Med Chem. 2007;14(17):1887–1892. doi: 10.2174/092986707781058832.
    1. Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J. 1994;128(1):7–11. doi: 10.1016/0002-8703(94)90003-5.
    1. Celi A, Cianchetti S, Dell’Omo G, Pedrinelli R. Angiotensin II, tissue factor and the thrombotic paradox of hypertension. Expert Rev Cardiovasc Ther. 2010;8(12):1723–1729. doi: 10.1586/erc.10.161.
    1. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262(2):157–172. doi: 10.1111/j.1365-2796.2007.01824.x.
    1. Koh KK, Quon MJ, Waclawiw MA. Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis. 2008;196(1):1–8. doi: 10.1016/j.atherosclerosis.2007.06.006.
    1. Vijayaraghavan K, Deedwania P. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention. Cardiol Clin. 2011;29(1):137–156. doi: 10.1016/j.ccl.2010.11.003.
    1. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med. 2000;45:419–429.
    1. Celi A, Del FA, Cianchetti S, Pedrinelli R. Tissue factor modulation by Angiotensin II: a clue to a better understanding of the cardiovascular effects of renin-angiotensin system blockade? Endocr Metab Immune Disord Drug Targets. 2008;8(4):308–313. doi: 10.2174/187153008786848259.
    1. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol. 1997;79(5A):12–16.
    1. Sechi LA, Novello M, Colussi G, Di FA, Chiuch A, Nadalini E. et al.Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage. Am J Hypertens. 2008;21(12):1347–1353. doi: 10.1038/ajh.2008.293.
    1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet. 1996;348(9038):1329–1339.
    1. Beguin S, Keularts I. On the coagulation of platelet-rich plasma. Physiological mechanism and pharmacological consequences. Haemostasis. 1999;29(1):50–57.
    1. Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med. 1993;117(1):71–77.
    1. Brodin E, Seljeflot I, Arnesen H, Hurlen M, Appelbom H, Hansen JB. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb Res. 2009;123(4):573–579. doi: 10.1016/j.thromres.2008.03.018.
    1. Kyrle PA, Westwick J, Scully MF, Kakkar VV, Lewis GP. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man–effect of low-dose aspirin. Thromb Haemost. 1987;57(1):62–66.
    1. Undas A, Undas R, Musial J, Szczeklik A. A low dose of aspirin (75 mg/day) lowers thrombin generation to a similar extent as a high dose of aspirin (300 mg/day) Blood Coagul Fibrinolysis. 2000;11(3):231–234.
    1. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2007;109(6):2285–2292. doi: 10.1182/blood-2006-01-010645.
    1. Matetzky S, Tani S, Kangavari S, Dimayuga P, Yano J, Xu H. et al.Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation. 2000;102(6):602–604. doi: 10.1161/01.CIR.102.6.602.
    1. Osnes LT, Foss KB, Joo GB, Okkenhaug C, Westvik AB, Ovstebo R. et al.Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kappa B/c-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor alfa (TNF-alpha) in human monocytes. Thromb Haemost. 1996;76(6):970–976.
    1. Dropinski J, Musial J, Jakiela B, Wegrzyn W, Sanak M, Szczeklik A. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin. Thromb Haemost. 2005;94(6):1300–1305.
    1. Herault JP, Dol F, Gaich C, Bernat A, Herbert JM. Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. Thromb Haemost. 1999;81(6):957–960.
    1. Eikelboom JW, Weitz JI, Budaj A, Zhao F, Copland I, Maciejewski P. et al.Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2002;23(22):1771–1779. doi: 10.1053/euhj.2000.3234.
    1. Kringen MK, Narum S, Lygren I, Seljeflot I, Sandset PM, Troseid AM. et al.Reduced platelet function and role of drugs in acute gastrointestinal bleeding. Basic Clin Pharmacol Toxicol. 2011;108(3):194–201. doi: 10.1111/j.1742-7843.2010.00643.x.
    1. Undas A, Stepien E, Branicka A, Wolkow P, Zmudka K, Tracz W. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Kardiol Pol. 2009;67(6):591–598.
    1. Leon C, Alex M, Klocke A, Morgenstern E, Moosbauer C, Eckly A. et al.Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood. 2004;103(2):594–600. doi: 10.1182/blood-2003-05-1385.
    1. Rao AK, Vaidyula VR, Bagga S, Jalagadugula G, Gaughan J, Wilhite DB. et al.Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost. 2006;96(6):738–743.
    1. Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factors. J Thromb Haemost. 2006;4(8):1747–1755. doi: 10.1111/j.1538-7836.2006.02000.x.
    1. Morange PE, Renucci JF, Charles MA, Aillaud MF, Giraud F, Grimaux M. et al.Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost. 2001;85(6):999–1003.
    1. Winckers K, Siegerink B, Duckers C, Maurissen LF, Tans G, Castoldi E. et al.Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study. J Thromb Haemost. 2011;9(11):2243–2250. doi: 10.1111/j.1538-7836.2011.04497.x.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する